Overview of purchasing channels, therapeutic applications and prices of pemetinib/pemetinib in China

Pemigatinib/Pemigatinib is a targeted drug targeting specific gene mutations. It has recently been launched in China, providing a new treatment option for patients with cholangiocarcinoma and myeloid/lymphoid tumors. Although the drug is not currently covered by medical insurance, it is already sold in some large general hospitals and specialized hospitals, and patients can purchase it under the guidance of a doctor's prescription.

Pemetinib is mainly used to treat cholangiocarcinoma (CCA) that has spread or cannot be surgically removed. It is especially suitable for patients who have undergone other cancer treatments and have FGFR2 gene abnormalities in their cancer. In addition, the drug is also used to treat myeloid/lymphoid tumors (blood cancers) that have relapsed or failed to respond to treatment in patients with FGFR1 gene abnormalities. Before using pemetinib, doctors will perform genetic testing to confirm whether a patient is a candidate for the drug.

Pemetinib is provided in the form of oral tablets, and the treatment process must be carried out under the guidance of an experienced physician. For patients with cholangiocarcinoma, the usual recommended dosing cycle is three weeks, with two weeks of daily pemetinib followed by one week off. Treatment can continue as long as the patient is benefiting from treatment and side effects are manageable.

In terms of price, the original drug of pemetinib is relatively expensive, and the specifications per box areFor doses of 4.5 mg and 9 mg, the price may range from RMB 30,000 to RMB 50,000. This is a significant financial burden for many patients. Therefore, when purchasing pemetinib, it is recommended that patients fully understand its price and possible preferential policies, and make a reasonable choice based on their own financial situation.

In general, pemetinib has been launched in China and provides a new treatment option for patients with cholangiocarcinoma and bone marrow/lymphoma. Although the price is higher and it is not covered by medical insurance, patients can still purchase the drug through doctors’ prescriptions in hospitals and other channels. During use, patients should strictly follow the doctor's instructions to ensure the safety and effectiveness of the treatment.